company background image
IDIA

Idorsia SWX:IDIA Stock Report

Last Price

CHF14.54

Market Cap

CHF2.6b

7D

0.1%

1Y

-45.0%

Updated

27 Jun, 2022

Data

Company Financials +
IDIA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

IDIA Stock Overview

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland.

Idorsia Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Idorsia
Historical stock prices
Current Share PriceCHF14.54
52 Week HighCHF26.58
52 Week LowCHF12.64
Beta0.73
1 Month Change-6.31%
3 Month Change-19.40%
1 Year Change-45.01%
3 Year Change-36.84%
5 Year Change-28.73%
Change since IPO6.52%

Recent News & Updates

Shareholder Returns

IDIACH BiotechsCH Market
7D0.1%1.2%3.8%
1Y-45.0%-17.9%-11.8%

Return vs Industry: IDIA underperformed the Swiss Biotechs industry which returned -19.4% over the past year.

Return vs Market: IDIA underperformed the Swiss Market which returned -12.4% over the past year.

Price Volatility

Is IDIA's price volatile compared to industry and market?
IDIA volatility
IDIA Average Weekly Movement7.2%
Biotechs Industry Average Movement7.8%
Market Average Movement4.6%
10% most volatile stocks in CH Market7.6%
10% least volatile stocks in CH Market2.4%

Stable Share Price: IDIA is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: IDIA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
2017n/aJean-Paul Clozelhttps://www.idorsia.com

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy.

Idorsia Fundamentals Summary

How do Idorsia's earnings and revenue compare to its market cap?
IDIA fundamental statistics
Market CapCHF2.57b
Earnings (TTM)-CHF727.62m
Revenue (TTM)CHF33.67m

76.5x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IDIA income statement (TTM)
RevenueCHF33.67m
Cost of RevenueCHF411.64m
Gross Profit-CHF377.97m
Other ExpensesCHF349.65m
Earnings-CHF727.62m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Jul 26, 2022

Earnings per share (EPS)-4.11
Gross Margin-1,122.70%
Net Profit Margin-2,161.29%
Debt/Equity Ratio-935.7%

How did IDIA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IDIA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDIA?

Other financial metrics that can be useful for relative valuation.

IDIA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue83.8x
Enterprise Value/EBITDA-4.3x
PEG Ration/a

Price to Book Ratio vs Peers

How does IDIA's PB Ratio compare to its peers?

IDIA PB Ratio vs Peers
The above table shows the PB ratio for IDIA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average11x
WBIO Wockhardt Bio
0.3xn/aCHF82.1m
MOLN Molecular Partners
0.9x-74.0%CHF230.8m
SANN Santhera Pharmaceuticals Holding
38.9x67.5%CHF51.7m
SFZN Siegfried Holding
3.9x12.1%CHF2.7b
IDIA Idorsia
n/a59.7%CHF2.6b

Price-To-Book vs Peers: IDIA is good value based on its Price-To-Book Ratio (-21.3x) compared to the peer average (11x).


Price to Earnings Ratio vs Industry

How does IDIA's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Book vs Industry: IDIA is good value based on its Price-To-Book Ratio (-21.3x) compared to the Swiss Biotechs industry average (0.7x)


Price to Book Ratio vs Fair Ratio

What is IDIA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDIA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-21.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IDIA's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of IDIA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IDIA (CHF14.54) is trading above our estimate of fair value (CHF10.78)

Significantly Below Fair Value: IDIA is trading above our estimate of fair value.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IDIA's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Idorsia forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


59.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDIA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IDIA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IDIA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IDIA's revenue (51.4% per year) is forecast to grow faster than the Swiss market (4.2% per year).

High Growth Revenue: IDIA's revenue (51.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IDIA is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Idorsia performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-25.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IDIA is currently unprofitable.

Growing Profit Margin: IDIA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IDIA is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.

Accelerating Growth: Unable to compare IDIA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IDIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).


Return on Equity

High ROE: IDIA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Idorsia's financial position?

Financial Health Score

2/6

Financial Health Score 2/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IDIA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: IDIA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: IDIA has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: IDIA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IDIA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IDIA has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 27.2% each year.


Discover healthy companies

Dividend

What is Idorsia current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IDIA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IDIA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IDIA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IDIA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IDIA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average management tenure


CEO

Jean-Paul Clozel (66 yo)

5.42yrs

Tenure

Mr. Jean-Paul Clozel, M.D., co- founded Actelion Ltd (alternate name Actelion AG ) in 1997 and has been its Chief Executive Officer since 1999. He is Executive Director at Idorsia Ltd. Mr. Clozel serves as...


Leadership Team

Experienced Management: IDIA's management team is seasoned and experienced (5.2 years average tenure).


Board Members

Experienced Board: IDIA's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.


Top Shareholders

Company Information

Idorsia Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Idorsia Ltd
  • Ticker: IDIA
  • Exchange: SWX
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CHF2.575b
  • Shares outstanding: 177.08m
  • Website: https://www.idorsia.com

Number of Employees


Location

  • Idorsia Ltd
  • Hegenheimermattweg 91
  • Allschwil
  • Basel-Landschaft
  • 4123
  • Switzerland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.